Responses after induction, consolidation, and whole program in patients with HGBCL and BL
| . | HGBCL (n = 22) . | BL (n = 46) . |
|---|---|---|
| Response to induction | ||
| Complete remission | 11 (50%) | 30 (65%) |
| Partial response | 8 (36%) | 12 (26%) |
| Progressive disease | 1 (4%) | 1 (2%) |
| Toxic deaths | 2 (9%) | 2 (4%) |
| Response to consolidation | ||
| Complete remission | 13 (59%) | 32 (70%) |
| Partial response | 3 (14%) | 4 (9%) |
| Progressive disease | 1 (4%) | 6 (13%) |
| Toxic deaths | 1 (4%) | 0 (0%) |
| Not performed | 5 (23%) | 3 (7%) |
| Response to the whole program | ||
| Complete remission | 16 (73%) | 36 (78%) |
| Partial response | 0 (0%) | 0 (0%) |
| Progressive disease | 3 (14%) | 7 (15%) |
| Toxic deaths | 3 (14%) | 2 (4%) |
| . | HGBCL (n = 22) . | BL (n = 46) . |
|---|---|---|
| Response to induction | ||
| Complete remission | 11 (50%) | 30 (65%) |
| Partial response | 8 (36%) | 12 (26%) |
| Progressive disease | 1 (4%) | 1 (2%) |
| Toxic deaths | 2 (9%) | 2 (4%) |
| Response to consolidation | ||
| Complete remission | 13 (59%) | 32 (70%) |
| Partial response | 3 (14%) | 4 (9%) |
| Progressive disease | 1 (4%) | 6 (13%) |
| Toxic deaths | 1 (4%) | 0 (0%) |
| Not performed | 5 (23%) | 3 (7%) |
| Response to the whole program | ||
| Complete remission | 16 (73%) | 36 (78%) |
| Partial response | 0 (0%) | 0 (0%) |
| Progressive disease | 3 (14%) | 7 (15%) |
| Toxic deaths | 3 (14%) | 2 (4%) |